AR062122A1 - Agonistas del subtipo ep2 del receptor de prostaglanina e - Google Patents
Agonistas del subtipo ep2 del receptor de prostaglanina eInfo
- Publication number
- AR062122A1 AR062122A1 ARP070103330A ARP070103330A AR062122A1 AR 062122 A1 AR062122 A1 AR 062122A1 AR P070103330 A ARP070103330 A AR P070103330A AR P070103330 A ARP070103330 A AR P070103330A AR 062122 A1 AR062122 A1 AR 062122A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cr10r11
- heterocyclyl
- aryl
- independently
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- -1 -N3 Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 230000004410 intraocular pressure Effects 0.000 abstract 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Son compuestos agonistas de EP2, composiciones farmacéuticas que contienen estos compuestos y procedimientos de uso de estos compuestos y composiciones para reducir la presion intraocular y tratar así el glaucoma. Reivindicacion 1: Un compuesto seleccionado el grupo que comprende el grupo de formulas (1) o una sal o solvato farmacéuticamente aceptable de los mismos, en los que R1 es alquilo C1-12, alquenilo C2-12, alquinilo C2-12, (CR2R3)b-X-alquilo C3-12, (CR2R3)b-X-cicloalquilo C3-12, (CR2R3)b-X-cicloalquenilo C2-12, (CR2R3)b-X-arilo C6-12 o (CR2R3)b-X-heterociclilo de 3 a 10 miembros, con la condicion de que R1 no sea terc-butilo, y en los que R1 está opcionalmente sustituido con 1 a 3 grupos R5; X es un enlace, O, -S- o -NR4; R2, R3 y R4 son cada uno independientemente H o alquilo C1-6; cada R5 es independientemente -CN, -OH, -F, -Cl, -Br, -I, -NO2, -CF3, -CHF2, -CH2F, -OCF3, -N3, alcoxi C1-6, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, -(C=O)R6, -(C=O)OR6, -O(C=O)R7, - O(C=O)NR7, -NR8(C=O)R9, -C(=O)NR8R9, -NR8R9, -NR8OR9, -S(O)jNR8R9, -S(O)j-alquilo C1-6, -OS(O)jR9, -NR8S(O)jR9, -(CR10R11)k-arilo C6-12, -(CR10R11)k-heterociclilo de 3 a 10 miembros, -(CR10R11)k-(C=O)(CR10R11)q-arilo C6-12, -(CR10R11)k-(C=O)- (CR10R11)q-heterociclilo de 3 a 10 miembros, -(CR10R11)k-O-(CR10R11)q-arilo C6-12, -(CR10R11)k-O-(CR10R11)q-heterociclilo de 3 a 10 miembros, -(CR10R11)k-S(O)j-(CR10R11)q-arilo C6-12 o (CR10R11)k-S(O)j-(CR10R11)q-heterociclilo de 3 a 10 miembros; cualquier alquilo C1-6, arilo C6-12 y heterociclilo de 3 a 10 miembros d los grupos R5 anteriores está cada uno opcionalmente sustituido independientemente con 1 a 3 sustituyentes, seleccionados cada uno independientemente de -CN, -F, -Cl, -Br, -I, - NO2, -CF3, -CHF2, -CH2F, -OCF3, -N3, -OR12, -(C=O)R12, -(C=O)OR13, -O(C=O)R13, -NR13(C=O)R14, -C(=O)NR15R16, -NR17R18, -NR14OR15, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, -(CR16R17)u-arilo C6-12 y -(CR16R17)u-heterociclilo de 3 a 10 miembros; R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 y R18 son cada uno independientemente H, alquilo C1-6, -(C=O)-N-alquilo C1-6, -(CR19R20)v-arilo C6-12 o -(CR10R20)v-heterociclilo de 3 a 10 miembros; cualquier alquilo C1-6, arilo C6-12 y heterociclilo de 3 a 10 miembros de los grupos R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 y R18 anteriores está opcionalmente sustituido cada uno independientemente con 1 a 3 sustituyentes, seleccionado independientemente cada uno de - CN, -OH, -F, -Cl, -Br, -I, -NO2, -NR21R22, -CF3, -CHF2, -CH2F, -OCF3, alquilo C1-6, alquenilo C2-6, alquinilo C2-6 y alcoxi C1-6; R19, R20, R21 y R22 son cada uno independientemente H o alquilo C1-6; 1 o 2 átomos cualquiera de C del heterociclilo de 3 a 10 miembros de cada uno de los grupos R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 y R18 está opcionalmente sustituido con oxo (=O); y en los que cualquiera de los sustituyentes anteriormente mencionados que comprenden un grupo - CH3 (metilo), -(CH2) (metileno) o -CH (metino) que no está unido a un grupo -F, -Cl, -Br, -I, -SO, o -SO2 o a un átomo de N, O o S, está opcionalmente sustituido independientemente con -OH, -F, -Cl, -Br, -I, alquilo C1-6, alcoxi C1-6, -NH2, -NH- alquilo C1-6 o -N(alquilo C1-6)2, j es 0, 1 o 2; y b, k, q, u y v son cada uno independientemente 0, 1, 2, 3, 4, 5 o 6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83390706P | 2006-07-28 | 2006-07-28 | |
| US94192307P | 2007-06-04 | 2007-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062122A1 true AR062122A1 (es) | 2008-10-15 |
Family
ID=38896126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103330A AR062122A1 (es) | 2006-07-28 | 2007-07-26 | Agonistas del subtipo ep2 del receptor de prostaglanina e |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7622475B2 (es) |
| EP (1) | EP2059507B1 (es) |
| JP (1) | JP4583500B2 (es) |
| KR (1) | KR101088942B1 (es) |
| AP (1) | AP2009004754A0 (es) |
| AR (1) | AR062122A1 (es) |
| AU (1) | AU2007280130B2 (es) |
| BR (1) | BRPI0714683A2 (es) |
| CA (1) | CA2659184C (es) |
| CL (1) | CL2007002207A1 (es) |
| CR (1) | CR10554A (es) |
| EA (1) | EA200970067A1 (es) |
| EC (1) | ECSP099071A (es) |
| GT (1) | GT200700064A (es) |
| HK (1) | HK1133876A1 (es) |
| IL (1) | IL196355A0 (es) |
| MA (1) | MA30604B1 (es) |
| MX (1) | MX2009001062A (es) |
| NO (1) | NO20090738L (es) |
| NZ (1) | NZ573964A (es) |
| PE (1) | PE20080408A1 (es) |
| RS (1) | RS20090002A (es) |
| TN (1) | TN2009000028A1 (es) |
| TW (1) | TWI372757B (es) |
| UY (1) | UY30511A1 (es) |
| WO (1) | WO2008015517A2 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2264009T3 (en) * | 2008-03-12 | 2019-04-15 | Ube Industries | PYRIDYLAMINE ACEDIC ACID COMPOUND |
| CA2757291C (en) | 2009-03-30 | 2017-05-23 | Ube Industries, Ltd. | Medical composition for treatment or prophylaxis of glaucoma |
| JPWO2011030864A1 (ja) * | 2009-09-11 | 2013-02-07 | 宇部興産株式会社 | アニリン化合物 |
| WO2011030873A1 (ja) * | 2009-09-11 | 2011-03-17 | 宇部興産株式会社 | ベンジル化合物 |
| WO2011030868A1 (ja) * | 2009-09-11 | 2011-03-17 | 宇部興産株式会社 | 置換カルボニル化合物 |
| WO2011030865A1 (ja) * | 2009-09-11 | 2011-03-17 | 宇部興産株式会社 | 置換ベンジル化合物 |
| WO2011030872A1 (ja) * | 2009-09-11 | 2011-03-17 | 宇部興産株式会社 | スルホンアミド化合物 |
| WO2011030871A1 (ja) * | 2009-09-11 | 2011-03-17 | 宇部興産株式会社 | Ｎ－置換ヘテロアリール化合物 |
| US20120259123A1 (en) * | 2009-12-25 | 2012-10-11 | Ube Industries, Ltd. | Aminopyridine compound |
| JP2013534251A (ja) * | 2010-08-17 | 2013-09-02 | アラーガン インコーポレイテッド | 角膜混濁を治療するためのｅｐ２またはｅｐ４アゴニスト |
| PE20142083A1 (es) | 2011-09-16 | 2014-12-30 | Fovea Pharmaceuticals | Derivados de anilina, su preparacion y su aplicacion terapeutica |
| CN104703598A (zh) * | 2012-01-20 | 2015-06-10 | 奥克塞拉有限公司 | 用于疾病治疗的取代的杂环化合物 |
| WO2013164326A1 (en) | 2012-05-03 | 2013-11-07 | Takeda Gmbh | Novel ep2 receptor agonists |
| US9339496B2 (en) * | 2012-07-13 | 2016-05-17 | Santen Pharmaceutical Co., Ltd. | Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist |
| JPWO2014157672A1 (ja) * | 2013-03-28 | 2017-02-16 | 宇部興産株式会社 | 置換ビアリール化合物 |
| JP2017206443A (ja) * | 2014-09-26 | 2017-11-24 | 宇部興産株式会社 | 置換ビアリール化合物及び他の医薬の組み合わせ |
| JP2017206445A (ja) * | 2014-09-26 | 2017-11-24 | 宇部興産株式会社 | 呼吸器疾患の治療及び／又は予防のための医薬組成物 |
| AR105215A1 (es) * | 2015-07-01 | 2017-09-13 | Santen Pharmaceutical Co Ltd | Formulación de depósito que contiene ésteres de ácido cítrico |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
| US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| UA59384C2 (uk) * | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
| UA67754C2 (uk) | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
| EP1000619A3 (en) * | 1998-06-23 | 2002-07-24 | Pfizer Products Inc. | Method for treating glaucoma |
| EP1108426A3 (en) | 1999-12-02 | 2002-10-02 | Pfizer Products Inc. | Use of prostaglandin agonists to treat erectile dysfunction or impotence |
| US20020161026A1 (en) * | 2000-11-07 | 2002-10-31 | Paralkar Vishwas M. | Combination therapies for the stimulation of bone growth |
| WO2003045371A1 (en) * | 2001-11-30 | 2003-06-05 | Pfizer Products Inc. | Pharmaceutical compositions and methods for administering ep2 receptor selective agonists |
| WO2003064391A1 (en) * | 2002-01-31 | 2003-08-07 | Pfizer Products Inc. | Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid |
| BRPI0408061A (pt) | 2003-03-04 | 2006-02-14 | Pfizer Prod Inc | tratamento médico utilizando um agonista de receptores seletivos de ep 2 |
| US20050203086A1 (en) * | 2004-03-04 | 2005-09-15 | Pfizer Inc. | Methods of treatment using an EP2 selective receptor agonist |
| US7915316B2 (en) * | 2005-08-22 | 2011-03-29 | Allergan, Inc | Sulfonamides |
| US7696235B2 (en) * | 2005-08-29 | 2010-04-13 | Allergan, Inc. | EP2 receptor agonists for treating glaucoma |
-
2007
- 2007-07-16 EA EA200970067A patent/EA200970067A1/ru unknown
- 2007-07-16 EP EP07766635A patent/EP2059507B1/en not_active Not-in-force
- 2007-07-16 MX MX2009001062A patent/MX2009001062A/es active IP Right Grant
- 2007-07-16 RS RSP-2009/0002A patent/RS20090002A/sr unknown
- 2007-07-16 BR BRPI0714683-3A patent/BRPI0714683A2/pt not_active IP Right Cessation
- 2007-07-16 AP AP2009004754A patent/AP2009004754A0/xx unknown
- 2007-07-16 AU AU2007280130A patent/AU2007280130B2/en not_active Ceased
- 2007-07-16 KR KR1020097001522A patent/KR101088942B1/ko not_active IP Right Cessation
- 2007-07-16 WO PCT/IB2007/002044 patent/WO2008015517A2/en active Application Filing
- 2007-07-16 JP JP2009522350A patent/JP4583500B2/ja not_active Expired - Fee Related
- 2007-07-16 NZ NZ573964A patent/NZ573964A/en not_active IP Right Cessation
- 2007-07-16 CA CA2659184A patent/CA2659184C/en not_active Expired - Fee Related
- 2007-07-26 PE PE2007000967A patent/PE20080408A1/es not_active Application Discontinuation
- 2007-07-26 AR ARP070103330A patent/AR062122A1/es unknown
- 2007-07-27 GT GT200700064A patent/GT200700064A/es unknown
- 2007-07-27 CL CL200702207A patent/CL2007002207A1/es unknown
- 2007-07-27 TW TW096127590A patent/TWI372757B/zh not_active IP Right Cessation
- 2007-07-27 UY UY30511A patent/UY30511A1/es not_active Application Discontinuation
- 2007-07-27 US US11/829,176 patent/US7622475B2/en not_active Expired - Fee Related
-
2009
- 2009-01-05 IL IL196355A patent/IL196355A0/en unknown
- 2009-01-13 CR CR10554A patent/CR10554A/es not_active Application Discontinuation
- 2009-01-14 EC EC2009009071A patent/ECSP099071A/es unknown
- 2009-01-26 TN TN2009000028A patent/TN2009000028A1/fr unknown
- 2009-01-28 MA MA31593A patent/MA30604B1/fr unknown
- 2009-02-16 NO NO20090738A patent/NO20090738L/no not_active Application Discontinuation
- 2009-10-07 US US12/575,373 patent/US20100105905A1/en not_active Abandoned
- 2009-11-10 HK HK09110479.0A patent/HK1133876A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062122A1 (es) | Agonistas del subtipo ep2 del receptor de prostaglanina e | |
| ES2647664T3 (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (AMD) | |
| AR062937A1 (es) | Compuestos que modulan el receptor cb2 | |
| ES2570127T3 (es) | Compuestos y composiciones como inhibidores de la proteína quinasa | |
| CO5690593A2 (es) | Nuevos derivados de pirimidin 2-amina | |
| AR062050A1 (es) | Derivados de amina utiles como agentes anti-cancerigenos | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR046767A1 (es) | Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1 | |
| AR064155A1 (es) | Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso | |
| CO6160296A2 (es) | Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| PE20081577A1 (es) | Derivados de sulfonamida ciclicos como inhibidores de la recaptacion de monoamina | |
| AR056964A1 (es) | Derivados de aminosulfonilo, composiciones farmaceuticas y sus usos | |
| PE20071254A1 (es) | Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion | |
| AR057855A1 (es) | Derivados de pirazina y composicion farmaceutica | |
| AR074130A1 (es) | Inhibidores de la diacilglicerol aciltransferasa | |
| AR048939A1 (es) | Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios. | |
| AR048260A1 (es) | Compuestos de heteroaril- y fenilsulfamoilo sustituidos | |
| AR059621A1 (es) | Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1 | |
| AR062965A1 (es) | Compuestos moduladores de receptores de glutamatometabotropicos mglur5, composiciones farmaceuticas que los contienen y usos terapeuticos en trastornos gastrointestinales, neurologicos y psiquiatricos agudos y cronicos | |
| AR077819A1 (es) | Compuestos heterociclicos antagonistas de esfingosina -1-fosfato (sip) | |
| AR044514A1 (es) | Acidos carboxilicos alfa sustituidos como moduladores ppar | |
| ATE484502T1 (de) | Neue verbindungen | |
| AR062405A1 (es) | Derivados de isoindol | |
| AR035230A1 (es) | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |